Universal Technical Institute, Inc. (UTI) is a Phoenix-based workforce education provider that operates the UTI and Concorde Career Colleges segments, delivering certificate and degree programs in automotive, diesel, aviation, welding, HVACR, electrical trades and allied healthcare. Shares were down 5.04% at $20.93 shortly after Thursday's opening bell, compared with Wednesday's close of $22.04.
The decline extends an overnight slide set off by the company's fiscal fourth-quarter report, published after Wednesday's close. The stock opened at $21.58, briefly traded as high as $22.74, then dropped to $20.23 before steadying — an intraday range of more than 11% and a sign that buyers and sellers are still fighting over the reset in expectations.
The decisive driver was the profit outlook. Fourth-quarter adjusted earnings of $0.32 per share badly trailed the $0.52 consensus, even though revenue rose 6% to $235.9 million and edged past estimates. Full-year revenue grew 7.4% to $897 million, with new student starts up 7% to 31,873 and average full-time active students up 6.6% to 26,251 — but net income fell 46.7% to $33.6 million, or $0.60 per diluted share.
The larger shock came from fiscal 2027 guidance. Management projected EPS of $0.00 to $0.09 and net income of $0 to $5 million, citing roughly $35 million of planned growth investment tied to four new campus openings and program expansions. Adjusted EBITDA was guided to $100 million to $106 million, while revenue of $925 million to $945 million topped the roughly $896 million consensus. In other words, the top line keeps growing while earnings compress toward zero during a heavy capital-spending cycle of $160 million to $170 million.
Quarterly student starts slowed to 3.3% growth from the full-year 7% pace, which management attributed to high-school admissions staffing gaps and limited program capacity. The company reaffirmed long-term targets of more than $1.2 billion in revenue and about $220 million in adjusted EBITDA by fiscal 2029, backed by up to 12 new campuses and roughly 45 new programs.
Sell-side revisions landed alongside the report. Lake Street cut its target to $29 from $37 while maintaining a Buy rating, arguing patient investors could be rewarded as the campus build-out drives revenue and margin expansion through fiscal 2029. Rosenblatt lowered its target to $35 from $45, and B. Riley moved to $39 from $45. Six of seven covering brokerages still rate the shares Buy or better, with one Hold and a median target near $35 — a spread that highlights how far sentiment has travelled without a full thesis break.
Volume was running at roughly three to four times the normal opening pace, with average daily turnover near 1.5 million shares against a market capitalization of about $1.2 billion. The move was not mirrored by the broader tape: the S&P 500 rose about 1.1% and the Nasdaq gained more than 2%, while education peers LOPE and STRA slipped only 1.8% and 2.5% respectively. The divergence confirms the selling was company-specific.
Technically, the stock is retesting its 50-day moving average near $20.90 after holding well above the 52-week low of $18.02, and it remains some 60% below the 52-week high of $51.34. The rebound off the session low suggests dip-buyers are defending the $20 area.
On a scale where 0 means no meaningful news and a move that is ordinary for the stock, and 100 means transformative news paired with an extreme, rare price move, the session scores 51 out of 100. The verified news was substantial: a 38% quarterly earnings miss, a fiscal 2027 EPS midpoint roughly 93% below the prior year, and multiple target cuts at a company valued near $1.2 billion.
The price reaction was large but not unusual for this name. At 5.04%, the decline was about 2.3 times the stock's average daily move, and five of the last 60 sessions produced equal or larger swings, including drops of 11.8% and 9.0%. Strong fundamental news combined with a moderate anomaly yields a mid-range score.
Attention shifts to fiscal first-quarter 2027 results, expected around mid-February, for evidence that new student starts are reaccelerating after the fourth-quarter slowdown. Investors will also watch enrollment disclosures tied to the high-school admissions rebuild, progress on four new campus openings, and any change to the $160 million-plus capital budget. Risks include execution slippage on the expansion, continued margin compression, a slower enrollment recovery, and sensitivity to federal student-aid policy and vocational funding cycles. Upside would require starts growth that outpaces the cost of new capacity.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. Bots vary widely by strategy, timeframe, performance metrics, and traded symbols, so the lineup changes as market conditions evolve. Reviewing the current leaders can help traders compare approaches and identify automated strategies that fit their own risk tolerance and time horizon.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for UTI moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 instances where the indicator moved out of the overbought zone. In 31 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 68 cases where UTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTI as a result. In 76 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence (MACD) for UTI just turned positive on November 10, 2026. Looking at past instances where UTI's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
UTI moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UTI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +16.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 259 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
UTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 183 of 250 cases where UTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. UTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.189) is slightly higher than the industry average of (1.158). UTI has a moderately high P/E Ratio (32.145) as compared to the industry average of (8.484). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.151) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of technical education
Industry OtherConsumerSpecialties